Smoking cessation after a urologic cancer diagnosis significantly benefits patients. It is not well known how often patients quit after diagnosis or how urologists intervene to support patients’ smoking cessation efforts.
(UroToday.com) For patients with muscle-invasive bladder cancer who are eligible for curative-intent treatment, cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy (RC) is a standard of care with improved pathologic response and overall survival (OS) compared to RC alone. However, recurrence rates, progression, and cancer-related death remain relatively high. Pembrolizumab is active in high-risk non-muscle invasive and […]
(UroToday.com) In a plenary presentation in the Navigating Uncertain Times in Muscle-Invasive and Advanced Bladder Cancer session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Dr. Apolo discussed uncertainties in the timing and sequence of therapies for patients with metastatic bladder cancer, emphasizing recent data, new approvals, and ongoing studies of emerging […]
(UroToday.com) For patients with muscle-invasive bladder cancer who are eligible for curative-intent treatment, cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is a standard of care with improved pathologic response and overall survival (OS) compared to RC alone. Consolidation with chemoradiotherapy (CRT) is an alternative to RC. Both of these consolidative approaches are associated with […]
(UroToday.com) In a plenary presentation in the Navigating Uncertain Times in Muscle-Invasive and Advanced Bladder Cancer session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Dr. Hoskin discussed uncertainties in trimodality therapy (TMT) for muscle invasive bladder cancer (MIBC).
(UroToday.com) Targeted therapies often rely on cell surface protein expression. One such potential target is dipeptidyl peptidase IV (DPP4), a cell surface protein also known as CD26 which expressed on a variety of cell types and with tumor- and tissue-dependent roles in cancer. It has been reported that patients treated with inhibitors of DPP4, from the field […]
(UroToday.com) Next-generation sequencing has increasingly been incorporated into the standard of clinical care for advanced prostate cancer. The most widely-acknowledged use is in the evaluation of genomic alterations in the genes controlling homologous recombination (HR), the apparatus for repairing double-stranded DNA breaks. Two FDA-approved agents (olaparib, rucaparib) exist for patients with tumors deficient in HR, both of […]
(UroToday.com) The treatment landscape for first-line therapy among patients with metastatic renal cell carcinoma (mRCC) has changed dramatically over the past 2 years. In 2018, the publication of the CheckMate214 data demonstrated a survival benefit for patients treated with nivolumab and ipilimumab compared with sunitinib in intermediate and poor-risk mRCC, ushering in the immunotherapy era for […]
(UroToday.com) The treatment landscape for first-line therapy among patients with metastatic renal cell carcinoma (mRCC) has changed dramatically over the past 2 years. In 2018, the publication of the CheckMate214 data demonstrated a survival benefit for patients treated with nivolumab and ipilimumab compared with sunitinib in intermediate and poor-risk mRCC, ushering in the immunotherapy era for […]
(UroToday.com) Docetaxel is a standard-of-care chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) patients that may potentiate antitumor immune responses, thus supporting its use in combination with nivolumab, which has shown limited antitumor activity in mCRPC as monotherapy. CheckMate 9KD (NCT03338790) is a phase 2 trial of nivolumab in combination with rucaparib, docetaxel, or enzalutamide for patients […]
